[go: up one dir, main page]

WO2003039480A3 - Method of treating disorder related to high cholesterol concentration - Google Patents

Method of treating disorder related to high cholesterol concentration Download PDF

Info

Publication number
WO2003039480A3
WO2003039480A3 PCT/US2002/035900 US0235900W WO03039480A3 WO 2003039480 A3 WO2003039480 A3 WO 2003039480A3 US 0235900 W US0235900 W US 0235900W WO 03039480 A3 WO03039480 A3 WO 03039480A3
Authority
WO
WIPO (PCT)
Prior art keywords
high cholesterol
treating
cholesterol concentration
disorder related
treating disorder
Prior art date
Application number
PCT/US2002/035900
Other languages
French (fr)
Other versions
WO2003039480A2 (en
Inventor
Shutsung Liao
Ching Song
Original Assignee
Univ Chicago
Shutsung Liao
Ching Song
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago, Shutsung Liao, Ching Song filed Critical Univ Chicago
Priority to AU2002356919A priority Critical patent/AU2002356919B2/en
Priority to CA002466033A priority patent/CA2466033A1/en
Priority to EP02802882A priority patent/EP1450816A4/en
Priority to JP2003541772A priority patent/JP2005508368A/en
Publication of WO2003039480A2 publication Critical patent/WO2003039480A2/en
Publication of WO2003039480A3 publication Critical patent/WO2003039480A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I). Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.
PCT/US2002/035900 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration WO2003039480A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002356919A AU2002356919B2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration
CA002466033A CA2466033A1 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration
EP02802882A EP1450816A4 (en) 2001-11-08 2002-11-08 METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION
JP2003541772A JP2005508368A (en) 2001-11-08 2002-11-08 Methods for treating diseases associated with high cholesterol levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
US60/348,020 2001-11-08

Publications (2)

Publication Number Publication Date
WO2003039480A2 WO2003039480A2 (en) 2003-05-15
WO2003039480A3 true WO2003039480A3 (en) 2003-06-19

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035900 WO2003039480A2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Country Status (5)

Country Link
EP (1) EP1450816A4 (en)
JP (1) JP2005508368A (en)
CA (1) CA2466033A1 (en)
TW (1) TW200300078A (en)
WO (1) WO2003039480A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
WO2006046593A1 (en) 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
US7902240B2 (en) 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X RECEPTOR AGONISTS
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN107936076B (en) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 Neuroactive steroids, compositions, and uses thereof
LT3932932T (en) 2013-03-13 2025-09-10 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND THEIR USES
HK1220472A1 (en) * 2013-03-13 2017-05-05 萨奇治疗股份有限公司 Neuroactive steroids, compositions, and uses thereof
JP2016193835A (en) * 2013-09-04 2016-11-17 学校法人常翔学園 Nuclear receptor liver X receptor agonist
MX2021011641A (en) 2013-12-24 2023-03-10 Durect Corp Uses of oxygenated cholesterol sulfates (ocs).
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE053778T2 (en) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
LT3812392T (en) 2015-07-06 2025-08-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202100468T1 (en) 2016-07-07 2021-09-14 Sage Therapeutics Inc 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
EP4101861A1 (en) 2016-08-02 2022-12-14 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
BR112019006365A2 (en) 2016-09-30 2019-08-06 Sage Therapeutics Inc c7 substituted oxisterols and methods of use thereof
IL293231B1 (en) 2016-10-18 2025-06-01 Sage Therapeutics Inc Oxysterols and methods of using them
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
EP0562849A2 (en) * 1992-03-27 1993-09-29 Eli Lilly And Company Steroid derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (en) * 1972-12-06 1974-07-24
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (en) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd Fluorine derivative of cholesterol
IT1255241B (en) * 1992-07-22 1995-10-20 Simos Contos BILIARY ACID DERIVATIVE AND ITS USE IN THERAPY
JP2002543216A (en) * 1999-04-30 2002-12-17 アーチ ディベロップメント コーポレイション Steroid derivatives
DK1392713T3 (en) * 2001-05-03 2008-02-18 Univ Chicago Liver X receptor agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
EP0562849A2 (en) * 1992-03-27 1993-09-29 Eli Lilly And Company Steroid derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCH. BIOCHEM. BIOPHYS., vol. 98, 1962, pages 305 - 311 *
DATABASE CAPLUS [online] WHITEHOUSE M. ET AL.: "Catabolism in vitro of cholesterol: some comparative aspects", XP002963337, accession no. STN Database accession no. 1962:464382 *
See also references of EP1450816A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851457B2 (en) 2016-10-18 2023-12-26 Sage Therapeutics Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
TW200300078A (en) 2003-05-16
EP1450816A4 (en) 2008-02-13
JP2005508368A (en) 2005-03-31
CA2466033A1 (en) 2003-05-15
WO2003039480A2 (en) 2003-05-15
EP1450816A2 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
WO2003039480A3 (en) Method of treating disorder related to high cholesterol concentration
MXPA05006194A (en) Methods of using a beverage composition.
BR0114576A (en) Compound, pharmaceutical composition, use of a compound, method of treating a disease state and process for preparing a compound
DE69512797D1 (en) Prostaglandin-synthase hemmer
WO2001052796A3 (en) Methods of using a beverage composition for treating dental erosion
BR0316375A (en) Diazinopyrimidines
NO20062292L (en) Procedure for treating transplant rejection
ATE410400T1 (en) METHOD FOR PRODUCING C13 ALCOHOL MIXTURES
MXPA03011681A (en) Methods of using soluble epoxide hydrolase inhibitors.
DE60024830T2 (en) METHOD FOR PRODUCING HETEROARYL SUBSTITUTED UREA BONDING
MXPA03009840A (en) Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments.
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
EA199800620A1 (en) SUBSTITUTED N - [(AMINOIMINOMETHYL OR AMINOMETHYL) PHENYL] PROPYLAMIDE
WO2005030120A3 (en) Antiangiogenic agents
WO2003024391A3 (en) Treatment and prevention of mucositis in cancer patients
WO2003009803A3 (en) Method of improving cognitive function
ATE250077T1 (en) STEROID SULFATASE INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF
AU1185801A (en) Novel compounds
AU2003300385A1 (en) Anticancer compounds
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
EA200600100A1 (en) DERIVATIVES NICOTINAMIDA USEFUL AS PDE4 INHIBITORS
CA2421990A1 (en) .beta.-thioamino acids
BR0312470A (en) Compound, use thereof, pharmaceutical composition, method of treating and / or preventing cancer, and process for preparing the compound
MY141593A (en) Anti-protozoal compositions
BR0308601A (en) plasma carboxypeptidase b inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2466033

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003541772

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002356919

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002802882

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802882

Country of ref document: EP